N- (2 -hydroxyethyl) -N-methyl4- (quinolin8-yl (1- (thiazol-4ylmethyl) piperidin4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression.

Details for Australian Patent Application No. 2010226996 (hide)

Owner AstraZeneca AB

Inventors Bui, Khanh; Dantzman, Cathy; Ernst, Glen; Hoesch, Valerie; Hudzik, Thomas; King, Megan Murphy; Liu, Jie; Yan, Jingbo

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2010226996

Parent 2007313515

Filing date 6 October 2010

Wipo publication date 28 October 2010

International Classifications

C07D 417/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

A61K 31/4709 (2006.01) - Non-condensed quinolines containing further heterocyclic rings

A61P 25/04 (2006.01) Drugs for disorders of the nervous system

A61P 25/16 (2006.01) Drugs for disorders of the nervous system

A61P 25/22 (2006.01) Drugs for disorders of the nervous system

A61P 25/24 (2006.01) Drugs for disorders of the nervous system

C07D 401/08 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

28 October 2010 Application Open to Public Inspection

  Published as AU-A-2010226996

28 October 2010 Complete Application Filed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010226997-Ceramic coatings and methods of making the same

2010226995-Image Sensing System, Software, Apparatus and Method For Controlling Combustion Equipment